You searched for side effects - Page 38 of 311 - Medivizor
Navigation Menu

Do patients with diabetes have a different antibody response to COVID-19 vaccines compared to healthy individuals?

Do patients with diabetes have a different antibody response to COVID-19 vaccines compared to healthy individuals?

Posted by on Mar 20, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the antibody response and side effects associated with COVID-19 vaccines administration in patients with type 1 (T1D) and type 2 diabetes (T2D), people without diabetes. The data showed similar immune responses in patients with and without diabetes after the second COVID-19 vaccine,...

Read More

Can high-frequency spinal cord stimulation provide relief to patients with painful diabetic nerve disease?

Can high-frequency spinal cord stimulation provide relief to patients with painful diabetic nerve disease?

Posted by on Mar 20, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the long-term impact of 10-kHz spinal cord stimulation (SCS) in patients with painful diabetic neuropathy (PDN; nerve disease) and refractory symptoms. The data supported the use of 10-kHz SCS for important, durable pain relief over 12 months in these patients. Some background Diabetic sensorimotor peripheral...

Read More

Investigating the effectiveness and safety of combining low-intensity extracorporeal shock wave therapy with tadalafil and L-arginine for the treatment of erectile dysfunction.

Investigating the effectiveness and safety of combining low-intensity extracorporeal shock wave therapy with tadalafil and L-arginine for the treatment of erectile dysfunction.

Posted by on Mar 20, 2022 in Erectile dysfunction | 0 comments

In a nutshell This study investigated the effectiveness and safety of combining low-intensity extracorporeal shock wave therapy (Li-ESWT) with tadalafil (Cialis) and L-arginine for the treatment of patients with mild and moderate erectile dysfunction (ED). The data showed that daily therapy with tadalafil and L-arginine increased the...

Read More

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

Evaluating the risk factors associated with radiation skin irritation after radiotherapy in patients with breast cancer

Posted by on Mar 20, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk factors associated with acute radiation dermatitis (ARD; skin irritation) after radiotherapy (RT) in patients with breast cancer (BC). The data showed that patients with diabetes, smokers, and those with a body mass index (BMI; a measure of body weight in relation to height) of more than 25 kg/m2 had a...

Read More

Evaluating quality of life in patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel

Evaluating quality of life in patients with relapsed or refractory multiple myeloma treated with idecabtagene vicleucel

Posted by on Mar 15, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the effect of idecabtagene vicleucel (ABECMA; ide-cel) treatment on health-related quality of life (HR-QoL) in patients with relapsed or refractory (r/r) multiple myeloma (MM).   This study concluded that this treatment improves HR-QoL for these patients.   Some...

Read More

Evaluating the effectiveness and safety of vagus nerve stimulation for improving arm function after ischemic stroke.

Evaluating the effectiveness and safety of vagus nerve stimulation for improving arm function after ischemic stroke.

Posted by on Feb 27, 2022 in Stroke | 0 comments

In a nutshell This study evaluated the effectiveness and safety of vagus nerve stimulation (VNS) for improving upper limb function in patients after ischemic stroke. The data showed that VNS was safe and improved upper limb function in these patients. Some background An ischemic stroke happens when blood flow through the blood vessels that supply...

Read More

Evaluating the effectiveness and safety of ropinirole for the treatment of Parkinson’s disease.

Evaluating the effectiveness and safety of ropinirole for the treatment of Parkinson’s disease.

Posted by on Feb 27, 2022 in Parkinson's Disease | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ropinirole (Requip) for the treatment of patients with Parkinson’s disease (PD). The data showed that ropinirole was effective in improving motor function and daily living of patients with PD but was associated with an increase in side effects. Some background Parkinson's...

Read More

Comparing the effectiveness and safety of TAS-102 with or without bevacizumab in patients with metastatic colorectal cancer.

Comparing the effectiveness and safety of TAS-102 with or without bevacizumab in patients with metastatic colorectal cancer.

Posted by on Feb 13, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of bevacizumab (Avastin) plus TAS-102 (Lonsurf; trifluridine-tipiracil) versus TAS-102 alone for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that bevacizumab combined with TAS-102 was effective with manageable side effects in improving the outcomes...

Read More

Which sequence of treatment should be given first – local or systemic treatment for patients with non-small cell lung cancer and brain metastases?

Which sequence of treatment should be given first – local or systemic treatment for patients with non-small cell lung cancer and brain metastases?

Posted by on Feb 13, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated which sequence of treatment should be given first, local or systemic (whole-body) treatment for patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs). The data showed that systemic treatment followed by local treatment was associated with longer survival for patients with NSCLC and BM. Some...

Read More

Comparing chiglitazar and sitagliptin effectiveness on glucose variations, insulin resistance and inflammation levels in patients with type 2 diabetes.

Comparing chiglitazar and sitagliptin effectiveness on glucose variations, insulin resistance and inflammation levels in patients with type 2 diabetes.

Posted by on Feb 13, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effectiveness of chiglitazar (Bilessglu) and sitagliptin (Januvia) on glycemic (blood glucose) variations, insulin resistance, and inflammation levels in patients with type 2 diabetes (T2D). The data showed that chiglitazar treatment was more effective at improving insulin resistance and inflammation compared...

Read More

Is chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?

Is chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?

Posted by on Feb 7, 2022 in Lung cancer | 0 comments

In a nutshell The study aimed to investigate the effectiveness and safety of atezolizumab (Tecentriq) versus best supportive care after chemotherapy in patients with resected early-stage non-small-cell lung cancer (NSCLC). The study showed atezolizumab is effective and has better outcomes than best supportive in these...

Read More

Evaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL

Evaluating therapies after CAR-T Cell treatment in patients with relapsed and refractory ALL

Posted by on Feb 6, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate if allogeneic hematopoietic stem cell transplant (alloHSCT) was a suitable treatment strategy for patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) after chimeric antigen receptor (CAR) T-cell therapy.   This study concluded that this was a suitable treatment...

Read More